1-3 of 3
Martha Derosier
Close
Sort by
Journal Articles

Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia

Clinical Trials & Observations
Paolo Ghia, Lydia Scarfò, Susan Perez, Kumudu Pathiraja, Martha Derosier, Karen Small, Christine McCrary Sisk, Nigel Patton
Journal: Blood
Blood (2017) 129 (13): 1876–1878.
https://doi.org/10.1182/blood-2016-10-748210
Published: 2017
Includes: Supplemental data
Journal Articles

A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib Compared to Ofatumumab in Patients with Refractory Chronic Lymphocytic Leukemia

Paolo Ghia, MD PhD, Lydia Scarfo, Kumudu Pathiraja, Martha Derosier, Karen Small, Nigel Patton
Journal: Blood
Blood (2015) 126 (23): 4171.
https://doi.org/10.1182/blood.V126.23.4171.4171
Published: 2015
Journal Articles

PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)

Craig H. Moskowitz, MD, Vincent Ribrag, MD, Jean-Marie Michot, MD, Giovanni Martinelli, MD, Pier Luigi Zinzani, MD, PhD, Martin Gutierrez, MD, Guadalupe De Maeyer, Alexandra G. Jacob, BS, Karen Giallella, Jennifer Weimer Anderson, Martha Derosier, Joy Wang, Zijiang Yang, Eric Rubin, MD, Shelonitda Rose, Margaret A. Shipp, MD, Philippe Armand, MD PhD
Journal: Blood
Blood (2014) 124 (21): 290.
https://doi.org/10.1182/blood.V124.21.290.290
Published: 2014